Genflow Biosciences PLC Admittance to trading on the OTCQB Venture Market (4646C)
13 Junio 2023 - 1:00AM
UK Regulatory
TIDMGENF
RNS Number : 4646C
Genflow Biosciences PLC
13 June 2023
Genflow Biosciences Plc
("Genflow" or "the Company")
Anti-Ageing Company, Genflow Biosciences, Announces Listing on
OTCQB Venture Market
in addition to its LSE Main Market Listing
Genflow has 3 Gene Therapies in Development Seeking to Treat
NASH and Werner Syndrome
Genflow Biosciences Plc ("Genflow" or "the Company") is pleased
to announce that, after a successful application process, its
Ordinary Shares ("Ordinary Shares") begin trading on the OTCQB
Venture Market in the United States ("US") today under the symbol
GENFF. Genflow will continue to trade on the London Stock Exchange
("LSE") Main Market under the symbol GENF, and, importantly, the
onboarding to this additional U.S. securities trading platform does
not involve any capital raise. The new U.S. trading facility
expands access to a broader pool of investors and enables investors
in the United States to trade during U.S. trading hours and in U.S.
dollars.
Eric Leire, CEO of Genflow, expressed his excitement about this
significant achievement, stating, "We are thrilled to announce that
Genflow Biosciences has been admitted to trading on the OTCQB
Venture Market in the United States. This move not only expands our
reach to a larger investor base and has the potential to enhance
liquidity for our shares, but also reinforces our unwavering
commitment to our primary listing on the prestigious London Stock
Exchange."
Tamara Joseph, Chair of the Board, also expressed her enthusiasm
on behalf of the Board of Directors, saying, "Genflow is developing
gene therapies that could address an important source of many
global illnesses: aging. As the Company moves into Phase I/II
clinical trials to treat potentially the orphan condition Werner
Syndrome, which causes premature aging, and NASH, a liver disease
that affects an estimated 35 million people around the world, it is
the right time to retain our London Stock Exchange listing while
adding easier access for US investors."
Further information on Genflow's application and the OTCQB
market is below:
As a Foreign Private Issuer, Genflow's admission to the OTC
Markets is subject to meeting the requirements for OTCQB, which
apply to international reporting companies. This includes
fulfilling the criteria for exemption under the US Exchange Act
Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption
includes the disclosure obligation to ensure that certain
information made public or distributed under home market
regulations is made publicly available on the Company's website or
other electronic information delivery system in English. Thus, the
Company will have no additional reporting obligations and incur
minimal ongoing costs; admission to the OTC Markets is subject to
meeting the requirements for OTCQB, which apply to international
reporting companies.
This includes fulfilling the criteria for exemption under the US
Exchange Act Rule 12g3-2(b) from SEC reporting. Under this
exemption, the Company must ensure that information made public or
distributed under its home market regulations is made available to
the public on its website or another electronic information
delivery system in English. Consequently, Genflow will have no
additional reporting obligations and will incur minimal ongoing
costs compared to traditional major exchanges.
As a verified market, the OTCQB offers transparent trading for
companies that have met a minimum bid price test, are current in
their financial reporting and have undergone an annual verification
and management certification process.
The cross-trading facility is provided through OTC Markets Group
Inc., located in New York. OTC Markets operates the world's largest
electronic interdealer quotation system for US broker-dealers and
offers multiple media channels to increase the visibility of
OTC-listed companies. Online brokers such as Ameritrade, Fidelity
Investments, Tradestation, Charles Schwab and E-trade all offer
OTCQB trades. US investors can find real-time quotes, market
information and access current company news and developments on a
BSF page on the OTC Markets website at www.otcmarkets.com.
Genflow appointed the corporate securities law firm Galanopoulos
& Company as its OTCQB Sponsor to support its onboarding to the
OTCQB Venture Market.
Additional information about the OTCQB market can be found at:
www.otcmarkets.com/learn/market-101
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
For further information please contact:
Genflow Biosciences Plc
Dr Eric Leire
Chief Executive Officer +32 477 495 881
-----------------
Clear Capital Markets
-----------------
Corporate Broker
Andrew Blaylock +44 203 869 6080
-----------------
Genflow Biosciences: Advancing Longevity and Healthspan
Genflow Biosciences is a UK-based biotechnology company
established in 2020. The company focuses on developing gene
therapies that target the aging process and aim to reduce and delay
age-related diseases. Their approach involves using
adeno-associated virus (AAV) vectors to deliver copies of the
Sirtuin-6 (SIRT6) gene variant found in centenarians to cells.
Genflow's mission is to increase the understanding of factors
that control and impact lifespan. They research, develop, and
commercialize therapeutic solutions to extend healthspan, enabling
longer and healthier lives. Genflow is dedicated to developing and
commercializing novel therapeutics for aging in both dogs and
humans. By addressing aging, Genflow aims to decrease healthcare
costs and alleviate the emotional and societal burden associated
with an aging population.
For more information, please visit www.genflowbio.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPURGQUPWGMP
(END) Dow Jones Newswires
June 13, 2023 02:00 ET (06:00 GMT)
Genflow Biosciences (LSE:GENF)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genflow Biosciences (LSE:GENF)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024